Recombinant rabbit monoclonal antibodies are produced using in vitro expression systems. The expression systems are developed by cloning in the specific antibody DNA sequences from immunoreactive rabbits. Then, individual clones are screened to select the best candidates for production. The advantages of using recombinant rabbit monoclonal antibodies include: better specificity and sensitivity, lot-to-lot consistency, animal origin-free formulations, and broader immunoreactivity to diverse targets due to larger rabbit immune repertoire.
Mitochondrial peripheral-type benzodiazepine receptor (PBR) is an indispensable element of the steroidogenic machinery, where it mediates the delivery of cholesterol to the inner mitochondrial side chain cleavage cytochrome P-450 upon ligand activation. PBR is composed of three subunits, an isoquinoline binding site, a voltage-dependent anion channel and an adenine nucleotide carrier. PBR is genetically conserved from bacteria to humans and in humans is widely expressed in peripheral organs, whereas in the brain, it is sparse and located mainly in glial cells. Peroxisome proliferator perfluordecanoic acid (PFDA) inhibits the Leydig cell steroidogenesis by affecting PBR mRNA stability, thus inhibiting PBR expression, cholesterol transport into the mitochondria and subsequent steroid formation. A cytoplasmic protein, PRAX-1 ( peripheral benzodiazepine receptor-associated protein 1), is found to specifically interact with PBR.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Protein Aliases: benzodiazepine peripheral binding site; benzodiazepine receptor, peripheral; isoquinoline-binding protein; Mitochondrial benzodiazepine receptor; OTTHUMP00000028891; PBR; Peripheral-type benzodiazepine receptor; PKBS; Translocator protein; translocator protein (18kDa)
Gene Aliases: BPBS; BZRP; DBI; IBP; MBR; mDRC; PBR; PBS; pk18; PKBS; PTBR; TSPO; Tspo1